First Trust Advisors LP Increases Stake in Repligen Corporation $RGEN

First Trust Advisors LP lifted its position in Repligen Corporation (NASDAQ:RGEN) by 1.8% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 266,290 shares of the biotechnology company’s stock after acquiring an additional 4,707 shares during the quarter. First Trust Advisors LP owned 0.47% of Repligen worth $35,595,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in RGEN. Brown Capital Management LLC raised its position in Repligen by 16.3% in the 2nd quarter. Brown Capital Management LLC now owns 1,005,276 shares of the biotechnology company’s stock worth $125,036,000 after purchasing an additional 141,241 shares during the period. Dimensional Fund Advisors LP boosted its position in shares of Repligen by 4.1% during the third quarter. Dimensional Fund Advisors LP now owns 799,510 shares of the biotechnology company’s stock valued at $106,826,000 after buying an additional 31,505 shares during the period. Stephens Investment Management Group LLC boosted its position in shares of Repligen by 14.4% during the third quarter. Stephens Investment Management Group LLC now owns 598,356 shares of the biotechnology company’s stock valued at $79,982,000 after buying an additional 75,509 shares during the period. Thrivent Financial for Lutherans grew its stake in shares of Repligen by 6.7% during the third quarter. Thrivent Financial for Lutherans now owns 458,820 shares of the biotechnology company’s stock valued at $61,331,000 after buying an additional 28,716 shares during the last quarter. Finally, Commonwealth of Pennsylvania Public School Empls Retrmt SYS grew its stake in shares of Repligen by 3,219.3% during the second quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 413,425 shares of the biotechnology company’s stock valued at $51,422,000 after buying an additional 400,970 shares during the last quarter. 97.64% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on RGEN. UBS Group decreased their price target on Repligen from $200.00 to $195.00 and set a “buy” rating for the company in a research note on Wednesday, February 25th. Barclays reduced their target price on Repligen from $200.00 to $175.00 and set an “overweight” rating on the stock in a research note on Wednesday, February 25th. Wells Fargo & Company decreased their target price on Repligen from $190.00 to $180.00 and set an “overweight” rating for the company in a research report on Wednesday, February 25th. Wall Street Zen lowered shares of Repligen from a “buy” rating to a “hold” rating in a research note on Saturday, February 28th. Finally, KeyCorp restated an “overweight” rating on shares of Repligen in a report on Wednesday, February 25th. One equities research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $174.58.

Insider Activity at Repligen

In other news, Director Karen A. Dawes sold 275 shares of the business’s stock in a transaction dated Wednesday, December 17th. The shares were sold at an average price of $161.00, for a total value of $44,275.00. Following the completion of the sale, the director owned 91,821 shares in the company, valued at approximately $14,783,181. The trade was a 0.30% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 1.20% of the company’s stock.

Repligen Price Performance

RGEN opened at $113.76 on Friday. The company has a market capitalization of $6.41 billion, a price-to-earnings ratio of 133.84, a PEG ratio of 2.32 and a beta of 1.14. The company has a current ratio of 8.37, a quick ratio of 7.12 and a debt-to-equity ratio of 0.26. Repligen Corporation has a 12-month low of $102.96 and a 12-month high of $175.77. The business’s fifty day simple moving average is $146.43 and its 200-day simple moving average is $146.72.

Repligen (NASDAQ:RGEN) last released its quarterly earnings data on Tuesday, February 24th. The biotechnology company reported $0.49 earnings per share for the quarter, beating the consensus estimate of $0.44 by $0.05. Repligen had a return on equity of 4.71% and a net margin of 6.62%.The firm had revenue of $197.91 million during the quarter, compared to the consensus estimate of $192.23 million. During the same period in the previous year, the company posted $0.44 earnings per share. The firm’s quarterly revenue was up 18.1% on a year-over-year basis. Repligen has set its FY 2026 guidance at 1.930-2.010 EPS. On average, equities research analysts anticipate that Repligen Corporation will post 1.72 earnings per share for the current fiscal year.

Repligen Company Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.